tiprankstipranks
Trending News
More News >
Helix BioPharma (TSE:HBP)
TSX:HBP
Canadian Market

Helix BioPharma (HBP) Stock Statistics & Valuation Metrics

Compare
25 Followers

Total Valuation

Helix BioPharma has a market cap or net worth of C$68.22M. The enterprise value is C$39.77M.
Market CapC$68.22M
Enterprise ValueC$39.77M

Share Statistics

Helix BioPharma has 74,155,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,155,760
Owned by Insiders
Owned by Institutions

Financial Efficiency

Helix BioPharma’s return on equity (ROE) is 102.93 and return on invested capital (ROIC) is 10265.95%.
Return on Equity (ROE)102.93
Return on Assets (ROA)-6.22
Return on Invested Capital (ROIC)10265.95%
Return on Capital Employed (ROCE)104.12
Revenue Per Employee0.00
Profits Per Employee-1.32M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Helix BioPharma is -5.52. Helix BioPharma’s PEG ratio is 0.32.
PE Ratio-5.52
PS Ratio0.00
PB Ratio-48.08
Price to Fair Value-568.43
Price to FCF-7.33
Price to Operating Cash Flow-7.34
PEG Ratio0.32

Income Statement

In the last 12 months, Helix BioPharma had revenue of 0.00 and earned -9.26M in profits. Earnings per share was -0.21.
Revenue0.00
Gross Profit-14.00K
Operating Income-9.37M
Pretax Income-9.40M
Net Income-9.26M
EBITDA-9.38M
Earnings Per Share (EPS)-0.21

Cash Flow

In the last 12 months, operating cash flow was -3.67M and capital expenditures -4.00K, giving a free cash flow of -3.68M billion.
Operating Cash Flow-3.67M
Free Cash Flow-3.68M
Free Cash Flow per Share-0.05

Dividends & Yields

Helix BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.93
52-Week Price Change-25.00%
50-Day Moving Average0.90
200-Day Moving Average0.94
Relative Strength Index (RSI)39.04
Average Volume (3m)1.38K

Important Dates

Helix BioPharma upcoming earnings date is Oct 24, 2025, TBA Not Confirmed.
Last Earnings DateJun 16, 2025
Next Earnings DateOct 24, 2025
Ex-Dividend Date

Financial Position

Helix BioPharma as a current ratio of 0.92, with Debt / Equity ratio of 0.00%
Current Ratio0.92
Quick Ratio0.92
Debt to Market Cap0.00
Net Debt to EBITDA0.12
Interest Coverage Ratio-1.34K

Taxes

In the past 12 months, Helix BioPharma has paid -132.00K in taxes.
Income Tax-132.00K
Effective Tax Rate0.01

Enterprise Valuation

Helix BioPharma EV to EBITDA ratio is -5.34, with an EV/FCF ratio of -9.57.
EV to Sales0.00
EV to EBITDA-5.34
EV to Free Cash Flow-9.57
EV to Operating Cash Flow-9.60

Balance Sheet

Helix BioPharma has C$2.00M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -C$2.00M billion.
Cash & Marketable SecuritiesC$2.00M
Total DebtC$0.00
Net Cash-C$2.00M
Net Cash Per Share-C$0.03
Tangible Book Value Per Share>-C$0.01

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Helix BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast-50.29%

Scores

Smart ScoreN/A
AI Score32.998
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis